Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Cancer Pain 3Pain, Intractable 2Pain 2

Interventions

Fentanyl 13Zoledronic Acid 8Ibandronic Acid 8nabiximols 6Oxycodone 6Tapentadol 5Morphine 4Hydromorphone 4Cryotherapy 4Cryosurgery 4alvimopan 3trimebutine 3-thiocarbamoylbenzenesulfonate 2resiniferatoxin 2cabozantinib 2Tetrodotoxin 2Radiation 2Prednisone 2Naloxone 2Diclofenac 2Analgesics, Opioid 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2ziconotide 1oxycodone naloxone combination 1imisopasem manganese 1fulranumab 1Xylitol 1Ultracet 1Transdermal Patch 1Therapeutics 1Sufentanil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pain × resiniferatoxin × Clear all
NCT05067257 2024-03-18

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Sorrento Therapeutics, Inc.

Phase 2 Suspended
120 enrolled

Cancer Pain, Pain, Pain, Intractable

NCT04572776 2021-11-09

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 3 Withdrawn

Cancer Pain, Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡